The PER Career Accelerator: What does Partner mean?
Annelie Murray, Life Sciences & Healthcare Consultant, has organised an exciting breakfast panel event, hosted by Gail McManus, for women who are interested in learning what it means to become a Partner and how to get there.
The morning will feature an engaging, interactive discussion covering key topics such as the timing and nature of important career conversations, the skills you should be honing to continue progressing, and how to recognise and leverage your own value effectively.
19 November 2024
Location
London
Register your interest
.png?v=638652021643010234)
Our panel are trailblazing women in Life Sciences and Healthcare funds who have all forged a path to Partnership. They’ll be sharing their diverse stories and some of the challenges they faced along the way.
Annelie's profile
Gail's profile
Meet our Panel
Diana Saraceni
Founder of Panakes, Diana has over 20 years of experience in managing Venture Capital investment funds and serving in companies’ boards across multiple geographies and sectors. After several years as a strategic consultant with A.T. Kearney, Diana worked as Senior Advisor in the Investment Banking division of Lazard. In 2001 she also co-founded 360 Capital Partners, a leading pan-European Venture Capital firm. She is a member of several national and international committees (EU and US) for the selection and promotion of innovative start-ups. She has also co-founded and chaired the International Venture Club.
She is frequently involved as Scientific Advisor to Life Sciences conferences and acting in or chairing juries for the allocation of public funds at Italian, European and US funds, such as Premio Marzotto, Life Star Awards, EIC H2020 and US National Cancer Institute-SBIR initiative.
Christina Takke
Christina co-founded V-Bio Ventures in 2015 and has since been a Managing Partner of the firm. Before launching V-Bio Ventures, Christina spent over 15 years in European Venture Capital, as consultant, analyst and investment manager. In her last position Christina was a Partner at Forbion Capital Partners, were she led and managed a series of successful investments in biopharmaceutical and pharmaceutical companies.
Christina has a scientific background, holding a PhD in Developmental Biology from the University of Cologne, Germany, and an MSc in Biology from the University of Darmstadt, Germany.
Dr Ena Prosser
Dr. Prosser has been with Fountain as Partner since the early days. Her investments include Calypso Therapeutics (sold to Novartis), KaNDy Therapeutics Ltd (sold to Bayer), Genable Ltd (sold to Spark), Inotrem and NeRRe Ltd. She is a PhD biotechnologist by training, with a broad range of interests in life science, government affairs, venture and patient focused charities.
Prior to helping establish Fountain, Dr. Prosser led Enterprise Ireland’s life science group where she assisted a number of Irish starts ups. Her industry career began at Elan, where she worked in product development, alliance management, M&A diligence and intellectual property. She is a member of the Institute of Directors.
Dr Heather Preston
Dr. Preston, MD, is a healthcare venture capitalist with over 30 years of experience. She is a Senior Advisor to TPG Biotech and serves on the boards of Oxford Biomedica, Oxford Nanopore, Aligos Therapeutics, and Azura Ophthalmics. Previously, she was a Managing Partner at Pivotal Bioventures and TPG Biotech, and held roles at JP Morgan Partners and New Enterprise Associates. Before investing, she led McKinsey's pharmaceutical and medical products consulting practice.
Dr. Preston earned a biochemistry degree from the University of London and a medical degree from Oxford. She completed a post-doctoral fellowship in molecular biology at Harvard's Dana-Farber Cancer Institute, trained in Internal Medicine at Massachusetts General Hospital, and specialized in Gastroenterology and Hepatology at UCSF.
Marianne Bjordal
Marianne joined 3B Future Health Fund in 2018 and was promoted to Partner in 2022. With over 20 years of experience in research and early-stage investment, she brings a wealth of scientific knowledge, rigour and curiosity to the team. Before joining 3B Future Health, Marianne was a researcher at the French National Centre for Scientific Research (CNRS), focusing on metabolism and growth control. She is a former Marie Curie Early-Stage Researcher and was honoured with the AXA Prize from the French Academy of Science in 2014.
She has previously served on the board of Gain Therapeutics Inc [GANX] and currently sits on the boards of NeoPhore Ltd, GenEp Inc, Epsilogen Ltd, Sibylla Biotech, and Kither Biotech.